Physician profile
Michael Latzka
NPI 1538127543
$7,776.65
in general payments reported to CMS, 2019-2025
69 companies · $762 in 2025
The $762 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $901 · 2020: $1,056 · 2021: $1,658 · 2022: $1,331 · 2023: $1,213 · 2024: $857 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,831.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $792.37 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $657.72 | 2019-2025 | |
| Pfizer INC. | $537.92 | 2019-2025 | |
| Glaxosmithkline, LLC. | $477.74 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $415.11 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $349.36 | 2019-2025 | Krystexxa, Evenity, Repatha |
| Abbott Laboratories | $345.68 | 2019-2025 | Freestyle Libre 3, Octrode |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.40 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $212.79 | 2019-2024 | Mounjaro, Jardiance |
| Daiichi Sankyo INC. | $209.72 | 2019-2024 | Injectafer |
| Mannkind Corporation | $192.28 | 2019-2023 | Afrezza |
| Sanofi-Aventis U.S. LLC | $181.60 | 2019-2023 | |
| Amarin Pharma, INC. | $178.34 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $173.42 | 2021-2025 | |
| Dexcom, INC. | $169.63 | 2021-2025 | Dexcom G6 Transmitter |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $166.11 | 2020-2025 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $151.66 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $144.68 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.14 | 2019-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $136.86 | 2019-2024 | |
| Medtronic, INC. | $127.14 | 2021-2024 | Intellis Adaptivestim, Corevalve Evolut R |
| Antares Pharma, INC. | $115.51 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Merck Sharp & Dohme LLC | $112.67 | 2020-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Astellas Pharma US INC | $106.79 | 2020-2025 | Veozah |
| Allergan, INC. | $82.53 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $80.66 | 2019-2024 | Strensiq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.17 | 2020-2022 | |
| Exact Sciences Corporation | $74.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $71.49 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $70.00 | 2022 | |
| Genentech USA, INC. | $61.57 | 2019-2020 | |
| Insulet Corporation | $53.53 | 2021 | |
| Sumitomo Pharma America, INC. | $50.28 | 2024-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $49.89 | 2024 | Voquezna |
| Seqirus USA INC | $44.99 | 2022-2025 | Flucelvax, Fluad |
| Xeris Pharmaceuticals, INC. | $35.11 | 2022-2024 | Gvoke Hypopen |
| Inari Medical, INC. | $33.52 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Shield Therapeutics INC | $32.59 | 2022-2025 | |
| Mylan Specialty L.P. | $31.86 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $30.97 | 2019-2024 | Spravato |
| Zealand Pharma US, INC. | $29.37 | 2020 | |
| Arbor Pharmaceuticals, INC. | $29.27 | 2020 | |
| Currax Pharmaceuticals LLC | $27.69 | 2020-2022 | |
| Recor Medical INC | $25.83 | 2025 | Paradise Ultrasound Renal Denervation System |
| Vbi Vaccine (Delaware) INC. | $25.30 | 2022 | |
| Ironwood Pharmaceuticals, INC | $23.85 | 2020 | |
| Stryker Corporation | $22.17 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Supernus Pharmaceuticals, INC. | $21.86 | 2022 | Xyosted |
| Abiomed | $21.75 | 2024 | Impella |
| Clarus Therapeutics INC. | $21.28 | 2021 | |
| Nabriva Therapeutics, Plc | $19.38 | 2021 | |
| Axsome Therapeutics, INC. | $19.07 | 2025 | Symbravo |
| Halozyme INC | $18.58 | 2023 | |
| Verona Pharma, INC. | $18.27 | 2025 | Ohtuvayre |
| Edwards Lifesciences Corporation | $17.75 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Cranial Technologies, INC | $16.07 | 2023 | Doc Band |
| E.R. Squibb & Sons, L.L.C. | $15.99 | 2019 | |
| Philips North America LLC | $15.56 | 2020 | |
| Vivus LLC | $15.36 | 2021 | |
| Inspire Medical Systems, INC. | $15.13 | 2025 | Inspire |
| Sanofi Pasteur INC. | $14.69 | 2022 | |
| Corcept Therapeutics | $14.63 | 2025 | Korlym |
| Adlon Therapeutics L.P. | $14.11 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.66 | 2023 | Quviviq |
| Upsher-Smith Laboratories LLC | $12.85 | 2019 | |
| Acerus Pharmaceuticals Corporation | $12.32 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.09 | 2022 | |
| Vistapharm, INC. | $11.67 | 2021 | |
| Strongbridge US INC. | $11.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Latzka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.